Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
In December 2019 SARS-CoV-2 virus appeared in the world, mainly appearing as an acute
infection of the lower respiratory tract. In March 2020, the World Health Organization (WHO)
announced a pandemic in relation to the disease caused by the SARS-CoV-2 virus, known as
COronaVIrus Disease 2019 (COVID-19). Since then, the efforts of scientists from around the
world have focused on finding the right treatment and vaccine for the new disease. COVID-19
has spread rapidly in a few months, affecting patients in all ages. The disease has a varied
course, patients can be 80% asymptomatic, but many develop respiratory failure, complicated
by sepsis and ultimately death. One of the possible complications associated with COVID-19
lung involvement is pulmonary fibrosis, leading to chronic breathing difficulties and
prolonged disability. No specific mechanisms leading to this phenomenon have been identified
in COVID-19, but some information is derived from previous studies on the SARS and MERS
epidemic. There have been several reports that the use of spironolactone may be important in
preventing pulmonary fibrosis.
The aim of the study is to evaluate the effectiveness of intravenous form of
mineralocorticoid receptor antagonist canrenoate potassium (an aldosterone antagonist of the
spirolactone group) in the treatment of COVID-19-associated pulmonary fibrosis based on the
mechanisms of the immune response.